BIO China: Intellectual Property Panel

  • Recommend
  • Tweet
  • Print
  • Email

Encouraging Innovation through Robust Patent Enforcement

Wednesday, October 12th, 4:00pm - 5:15pm

A panel of experts will explore how enforcement of IP can support the goals of the 12th Five-Year plan in a competitive global economy.  The panel will explore the challenges to enforcement in face of limited resources and will compare and contrast enforcement in the US and China.

Moderator:

  •  Frank S. DiGiglio, Managing Partner, Scully Scott Murphy & Presser PC  

Panelists:

  • Brian P. Barrett, R.Ph., JD, Senior Director, Assistant General Patent Counsel, Eli Lilly
  • David Shen, Regional Legal Counsel, AstraZeneca
  • Tina Tai, Patent Attorney, Attorney at law, Assistant General Manager, China Patent Agent (H.K.) Ltd.

 


Who's Who


 

Brian P. Barrett - Brian Barrett is Senior Director - Assistant General Patent Counsel at Eli Lilly and Company, Indianapolis, Indiana.  He practices patent prosecution and patent litigation strategy.  He joined Lilly in 1988.  He is a member of the Indiana Bar Association, American Intellectual Property Law Association, Intellectual Property Owners Association and the Biotechnology Industry Organization (BIO).  He is a former chairman of BIO’s Intellectual Property Counsels Committee and currently chairs BIO’s amicus committee.  Mr. Barrett has degrees in chemistry and pharmacy and graduated with honors from the Indiana University School of Law-Indianapolis in 1994.  He is admitted to the bars of Indiana and the Federal Circuit, and is admitted to practice before the U.S. Supreme Court.

Frank S. DiGiglio - Frank DiGiglio received his B.S. in Biology from Boston College in 1975 and his J.D. from St. John's University School of Law in 1982. He was admitted to the N.Y. State Bar in 1983, the U.S. District Court, Southern and Eastern Districts of N.Y., N.Y. State Court of Appeals for the Second Circuit and U.S. Court of Appeals, and Federal Circuit. Mr. DiGiglio is registered to practice before the U.S. Patent and Trademark Office and is a member of the N.Y.S. Biotechnology Association, NYIPA and AIPLA. Mr. DiGiglio is an Adjunct Professor at Benjamin N. Cardozo School of Law (Yeshiva University) in Pharmaceutical and Biotechnology Patent Law. Mr. DiGiglio is experienced in patent and trademark litigation; extensive interference practice; Federal Circuit appeal practice; with technical emphasis in biotechnology, biochemistry and pharmaceutical sciences.

Tina Tai - Ms. Tai received, from Peking University, her B.S. in Applied Chemistry in 1990 and M.S. in Polymer Chemistry in 1993. She joined CPA in 1993, and qualified as a patent attorney in 1994. Ms. Tai was admitted to practice law in 1999. She took the LLM program at the University of London from 2002 to 2003. She received further training at a famous company in Germany in 1997, and at other German and British law firms in 2001. She participated in the Research Project on the Third Amendment to the Chinese Patent Law in 2005. As a patent attorney, Ms. Tai has represented many of our important Chinese and foreign clients in renowned invalidation cases and lawsuits. She represented Pfizer. Inc. as the chief attorney in both invalidation proceedings and court procedure involving the “Viagra” case. Besides, she is skillful in drafting patent application documents in such fields of technology as polymer, pharmaceutical chemistry, organic chemistry, organic synthesis, and experienced in preparing responses to office actions in the substantive examination proceedings, in handling cases of patent reexamination, invalidation and patent-related administrative litigation and infringement lawsuits, and in making infringement analysis. Ms. Tai is a council member of the China Intellectual Property Society, a member of the Chinese Group of AIPPI, a member of the board of All-China Patent Agents Association and a member of LES China. Working language: Chinese, English, German and Japanese.